{"status":"success","data":{"title":"Angioedema","slug":"angioedema","tags":["ACE inhibitor,"],"collection":["Allergy-Immunology"],"content":"<h1 id=\"angioedema\">Angioedema</h1>\n<p><strong>Definition</strong>: self-limited, asymmetric, localized, non-pitting swelling</p>\n<p><strong>Background</strong></p>\n<ul>\n<li>15% of population</li>\n<li>50% with urticaria</li>\n<li><em>Common sites:</em> perioribtal, lips, tongue, extremity, bowel wall</li>\n<li><em>Main cause of death:</em> Laryngeal edema (25-40% mortality if present)</li>\n</ul>\n<h2 id=\"syndromes-and-specific-treatments\">Syndromes and Specific Treatments</h2>\n<p><strong>Idiopathic Angioedema</strong></p>\n<ul>\n<li>38% of patients with angioedema</li>\n</ul>\n<p><strong>Allergic or IgE Mediated Angioedema</strong></p>\n<ul>\n<li>Type I hypersensitivity reaction</li>\n<li>Commonly from food or medications</li>\n<li><em>Tx:</em> allergen avoidance, antihistamine, H2 blockers, glucocorticoid, epinephrine for laryngeal edema</li>\n</ul>\n<p><strong>Hereditary Angioedema</strong></p>\n<ul>\n<li>C1q esterase inhibitor deficiency</li>\n<li><em>Triggers:</em> trauma (especially dental trauma), anxiety, menstruation, infection, exercise, alcohol consumption, stress</li>\n<li><em>Prophylaxis tx:</em> <strong>danazol</strong> better than tranexamic acid and aminocaproic acid</li>\n<li><em>Acute tx:</em>  <strong>FFP</strong> (or C1 inhibitor concentrate - given in Europe/Canada only)</li>\n<li>Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema</li>\n</ul>\n<p><strong>ACE Inhibitor Angioedema</strong></p>\n<ul>\n<li>Up to 2.2% of those taking ACE-I&#39;s</li>\n<li>From elevated levels of bradykinin</li>\n<li>Highest incidence during 1st month of starting medication, but can occur years after </li>\n<li>5x more common in African-Americans compared to Caucasians</li>\n<li>Controversial whether patient can take ARBs (doesn’t cause elevated bradykinin) as well – some with angioedema.</li>\n<li><em>Tx: </em> discontinue medication and supportive care</li>\n<li>Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema</li>\n</ul>\n<p><strong>Treatment philosophy:</strong> </p>\n<ul>\n<li>Low threshold to protect airway by intubation</li>\n<li><strong><em>Pearl:</em></strong> Be sure to prescribe patients Epi-pen if discharged home</li>\n<li><em>Fiberoptic nasopharyngoscopy</em>: consider performing on all patients with voice change to look for largnyeal edema</li>\n</ul>\n<h2 id=\"admission-guidelines-for-angioedema\">Admission guidelines for angioedema</h2>\n<p>(<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684\">Ishoo et al., Head Neck Surg, 1999</a>)  </p>\n<ul>\n<li>93 episodes in 80 patients (1985-95) with no deaths </li>\n<li>9.7% cases required intubation/tracheostomy</li>\n<li><em>Causes:</em> 39% from <span class=\"drug\">ACE-I</span></li>\n<li><em>Disposition:</em> 25% outpt, 23% floor, 53% ICU</li>\n<li>ICU admissions correlated with voice change, hoarseness, dyspnea, rash </li>\n<li>Airway intervention correlated with voice change, hoarseness, dyspnea, stridor</li>\n</ul>\n<p><strong>Proposed staging system:</strong></p>\n<ul>\n<li><strong>Stage I:</strong> Facial rash, facial edema, lip edema - outpatient</li>\n<li><strong>Stage II</strong>: Soft palate edema – outpatient or floor</li>\n<li><strong>Stage III:</strong> Lingual edema --&gt; ICU (7% required airway intervention)</li>\n<li><strong>Stage IV:</strong> Laryngeal edema –&gt; ICU (24% required airway intervention)</li>\n</ul>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684\">Ishoo E et al. Predicting airway risk in angioedema: Staging system based on presentation. Otolaryngol Head Neck Surg 1999; 121:263-8.</a></li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684\">Temino VM, Peebles RS. Spectrum and Treatment of Angioedema. Am J Med 2008; 121: 282-6</a></li>\n<li><a href=\"http://emedicine.medscape.com/\">Emedicine.com</a></li>\n</ul>\n"}}